About Amgen
Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care and outcomes by providing effective therapeutic solutions.
Thousand Oaks, CaliforniaHeadquarters
1980Year Founded
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees
Risks
Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
FTC scrutiny of mergers may complicate Amgen's future growth strategy.
Advancements in quantum technologies could pose a competitive threat to Amgen.
Differentiation
Amgen focuses on biologic therapies derived from living organisms.
The company has a strong pipeline of potential new therapies in development.
Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.
Upsides
Amgen's investment in AI aligns with trends in biotechnology innovation.
Institutional investments indicate strong market confidence in Amgen's growth.
FTC clearance of the Horizon merger may ease future regulatory hurdles.
Funding
Total raised$28.5 K
StageIPO
POST IPO EQUITY
12/31/2023$14
POST IPO DEBT
11/30/2022$28.5 K